Acadia Pharmaceuticals (ACAD) analyst forecast and price target
Analyst forecast
Consensus of 21 analyst ratings
Based on 12 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Morgan Stanley | Maintained | Equal-Weight | $28.00 from $27.00 | Aug 25, 2026 |
| Citigroup | Maintained | Buy | $40.00 from $39.00 | Aug 25, 2026 |
| Deutsche Bank | Maintained | Buy | $38.00 from $37.00 | Aug 25, 2026 |
| UBS | Maintained | Buy | $49.00 from $45.00 | Aug 17, 2026 |
| Needham | Maintained | Buy | $41.00 from $38.00 | Aug 12, 2026 |
| Citigroup | Maintained | Buy | $39.00 from $35.00 | Aug 10, 2026 |
| RBC Capital | Maintained | Outperform | $37.00 from $36.00 | Aug 5, 2026 |
| Citizens | Maintained | Market Outperform | $36.00 from $35.00 | Aug 5, 2026 |
| Oppenheimer | Maintained | Perform | $25.00 from $23.00 | Aug 5, 2026 |
| Stifel | Maintained | Hold | $25.00 from $24.00 | Jul 21, 2026 |
| BMO Capital | Maintained | Outperform | $36.00 from $34.00 | Jul 21, 2026 |
| RBC Capital | Maintained | Outperform | $36.00 from $29.00 | Jul 7, 2026 |
| B of A Securities | Maintained | Buy | $30.00 from $29.00 | Jun 30, 2026 |
| Canaccord Genuity | Maintained | Buy | $36.00 from $32.00 | Jun 29, 2026 |
| Citigroup | Maintained | Buy | $35.00 from $32.00 | Jun 29, 2026 |
| Citigroup | Maintained | Buy | $32.00 from $33.00 | May 8, 2026 |
| B of A Securities | Upgraded | Neutral → Buy | $29.00 | Mar 25, 2026 |
| JP Morgan | Maintained | Overweight | $34.00 from $31.00 | Mar 4, 2026 |
| Stifel | Maintained | Hold | $24.00 from $25.00 | Feb 26, 2026 |
| RBC Capital | Maintained | Outperform | $30.00 from $31.00 | Feb 26, 2026 |
Frequently asked questions
What is the price target for ACAD stock?
The average 12-month analyst price target for Acadia Pharmaceuticals (ACAD) is $35.08, with a high estimate of $49.00 and a low of $25.00, across 12 analysts.
Is ACAD a buy, sell, or hold?
Analysts covering Acadia Pharmaceuticals currently average a Buy rating: 16 buy, 4 hold and 1 sell, from 21 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for ACAD?
The average price target of $35.08 implies 21.35% upside from the last price of $28.91.
What is the latest analyst rating on ACAD?
On Aug 25, 2026, Morgan Stanley maintained Acadia Pharmaceuticals at Equal-Weight with a price target of $28.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.